The Employees' State Insurance Corporation (ESIC) on February 25, 2026, notified regarding the downward Rate Revision for Item No. 1813 under DESIC RC-167 of the approved pharmaceutical firm M/s Merck Specialties Private Limited.
It notifies a downward revision of rates under the DGESIC Rate Contract for Item No. 167 (RC 1813 – L1), Cetuximab Injection 500 mg/100 ml (Erbitux) manufactured by Merck Healthcare KGaA, Germany. The approved rate has been reduced from ₹79,055.09 per vial to ₹73,000 per vial (GST extra as applicable). The difference in rates is to be recovered for all supply orders placed on or after December 11, 2025.
The revision has been issued at the request of M/s Merck Specialties Private Limited. The drug shall continue to conform to the composition, strength, standards, and packaging approved under the DGESIC Rate Contract and comply with the provisions of the Drugs & Cosmetics Act and related amendments. All DDOs are directed to recover the excess amount paid (rate difference) from subsequent bills of the firm and maintain proper records.
[Notification no. - U-25/12/RC/RateRevision/2026/Med.V (E:1550528)/58]
